The present study has been undertaken to evaluate two aspects: (i) the possible co-infection of MP and CP in COVID-19 by the serological assessment of specific antibodies; and (ii) the possible role of both MP and CP as cofactors worsening COVID-19 clinical manifestations and outcomes. This evidence concerns the gene CP and COVID-19.